GSK wins yet another reprieve for blockbuster Advair franchise as Mylan is hit (again) with a CRL

Wednesday evening Mylan reported that the FDA had kicked back its copycat version of Advair, again. This follows a whole slate of rejections for companies looking to grab the mega-blockbuster franchise away with cheaper copies of the respiratory drug.